PI
TVTX icon

Putnam Investments’s Travere Therapeutics TVTX Stock Holding History

Putnam Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-49,740
Closed -$1.23M – 1199
2022
Q3 		$1.23M Sell
49,740
-905
-2% -$23.4K ﹤0.01% 824
2022
Q2 		$1.23M Sell
50,645
-626
-1% -$15.7K ﹤0.01% 828
2022
Q1 		$1.32M Sell
51,271
-3,775
-7% -$100K ﹤0.01% 867
2021
Q4 		$1.71M Buy
+55,046
New +$1.55M ﹤0.01% 788
2015
Q4 		– Sell
-535,328
Closed -$10.8M – 1487
2015
Q3 		$10.8M Sell
535,328
-182,185
-25% -$5.4M 0.02% 430
2015
Q2 		$23.8M Sell
717,513
-325,839
-31% -$8.92M 0.05% 309
2015
Q1 		$25M Buy
1,043,352
+194,577
+23% +$2.97M 0.05% 303
2014
Q4 		$10.4M Sell
848,775
-88,603
-9% -$917K 0.02% 492
2014
Q3 		$8.46M Sell
937,378
-3,558
-0.4% -$41.9K 0.02% 542
2014
Q2 		$11M Sell
940,936
-472,626
-33% -$6.4M 0.02% 454
2014
Q1 		$30.1M Buy
+1,413,562
New +$21.7M 0.07% 267

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Putnam Investments's TVTX Position: Q4 2022 in Review

Putnam Investments sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 49,740 shares — an estimated $1.23M sold.

Putnam Investments first reported a position in TVTX in Q1 2014 and held it in 11 quarters. The position peaked at $30.1M in Q1 2014. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

  • Putnam Investments reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Putnam Investments sold 49,740 Travere Therapeutics shares in Q4 2022, an estimated $1.23M.
  • Putnam Investments first reported a position in Travere Therapeutics in Q1 2014 and held it in 11 quarters.
  • Putnam Investments's Travere Therapeutics position peaked at $30.1M in Q1 2014.
  • 155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on Putnam Investments's 13F filing for Q4 2022, filed 14 Feb 2023.